Sunesis Pharmaceuticals (NASDAQ:SNSS) Receives Hold Rating from Cowen
Cowen reiterated their hold rating on shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) in a research report sent to investors on Sunday morning, TipRanks reports.
Several other equities analysts have also commented on SNSS. Zacks Investment Research raised Sunesis Pharmaceuticals from a hold rating to a buy rating and set a $1.25 target price for the company in a report on Wednesday, May 15th. ValuEngine upgraded Sunesis Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, May 24th. HC Wainwright reiterated a hold rating and set a $2.00 price objective on shares of Sunesis Pharmaceuticals in a research report on Monday. Finally, Oppenheimer set a $6.00 price objective on Sunesis Pharmaceuticals and gave the stock a buy rating in a research report on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $3.08.
NASDAQ:SNSS opened at $0.68 on Friday. The company has a market cap of $56.56 million, a PE ratio of -0.91 and a beta of 2.98. Sunesis Pharmaceuticals has a 52 week low of $0.20 and a 52 week high of $2.60.
Hedge funds and other institutional investors have recently modified their holdings of the company. Aisling Capital Management LP acquired a new position in shares of Sunesis Pharmaceuticals during the fourth quarter worth approximately $1,092,000. Fosun International Ltd acquired a new position in shares of Sunesis Pharmaceuticals during the first quarter worth approximately $863,000. Finally, Algert Global LLC acquired a new position in shares of Sunesis Pharmaceuticals during the first quarter worth approximately $25,000. Institutional investors and hedge funds own 43.10% of the company’s stock.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Further Reading: Stock Symbols and CUSIP Explained
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.